AlzeCure Pharma places 9,926,099 shares with QuantumCell at SEK 4.91 each
Reuters2026/08/03 06:07- AlzeCure Pharma set a directed share issue to QuantumCell as part of the ACD856 out-licensing and collaboration agreement.
- QuantumCell will subscribe for 9,926,099 new shares at SEK 4.91 each, paid in cash.
- The placement implies about 6.7% dilution; total shares to rise to 147,823,445 once registered.
- The transaction corresponds to a USD 5 million equity component previously disclosed under the agreement.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
Crypto prices
More
